These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23018916)

  • 21. Six-Month Response to Delamanid Treatment in MDR TB Patients.
    Hewison C; Ferlazzo G; Avaliani Z; Hayrapetyan A; Jonckheere S; Khaidarkhanova Z; Mohr E; Sinha A; Skrahina A; Vambe D; Vasilyeva I; Lachenal N; Varaine F
    Emerg Infect Dis; 2017 Oct; 23(10):1746-8. PubMed ID: 28767036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
    Master I; Furin J
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):985-7. PubMed ID: 27287655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delamanid in the treatment of multidrug-resistant tuberculosis.
    Gupta R; Wells CD; Hittel N; Hafkin J; Geiter LJ
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):33-37. PubMed ID: 28240570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
    Sotgiu G; Pontali E; Centis R; D'Ambrosio L; Migliori GB
    Expert Rev Anti Infect Ther; 2015 Mar; 13(3):305-15. PubMed ID: 25645397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
    Koirala S; Borisov S; Danila E; Mariandyshev A; Shrestha B; Lukhele N; Dalcolmo M; Shakya SR; Miliauskas S; Kuksa L; Manga S; Aleksa A; Denholm JT; Khadka HB; Skrahina A; Diktanas S; Ferrarese M; Bruchfeld J; Koleva A; Piubello A; Koirala GS; Udwadia ZF; Palmero DJ; Munoz-Torrico M; Gc R; Gualano G; Grecu VI; Motta I; Papavasileiou A; Li Y; Hoefsloot W; Kunst H; Mazza-Stalder J; Payen MC; Akkerman OW; Bernal E; Manfrin V; Matteelli A; Mustafa Hamdan H; Nieto Marcos M; Cadiñanos Loidi J; Cebrian Gallardo JJ; Duarte R; Escobar Salinas N; Gomez Rosso R; Laniado-Laborín R; Martínez Robles E; Quirós Fernandez S; Rendon A; Solovic I; Tadolini M; Viggiani P; Belilovski E; Boeree MJ; Cai Q; Davidavičienė E; Forsman LD; De Los Rios J; Drakšienė J; Duga A; Elamin SE; Filippov A; Garcia A; Gaudiesiute I; Gavazova B; Gayoso R; Gruslys V; Jonsson J; Khimova E; Madonsela G; Magis-Escurra C; Marchese V; Matei M; Moschos C; Nakčerienė B; Nicod L; Palmieri F; Pontarelli A; Šmite A; Souleymane MB; Vescovo M; Zablockis R; Zhurkin D; Alffenaar JW; Caminero JA; Codecasa LR; García-García JM; Esposito S; Saderi L; Spanevello A; Visca D; Tiberi S; Pontali E; Centis R; D'Ambrosio L; van den Boom M; Sotgiu G; Migliori GB
    Pulmonology; 2021; 27(5):403-412. PubMed ID: 33753021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
    Mok J; Kang H; Koh WJ; Jhun BW; Yim JJ; Kwak N; Lee T; Kang B; Jeon D
    Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31285308
    [No Abstract]   [Full Text] [Related]  

  • 28. Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
    Ghosh S; Breitscheidel L; Lazarevic N; Martin A; Hafkin J; Hittel N
    Eur Respir J; 2021 May; 57(5):. PubMed ID: 33243846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
    Dawson R; Diacon AH; Takuva S; Liu Y; Zheng B; Karwe V; Hafkin J
    Trials; 2024 Jan; 25(1):70. PubMed ID: 38243296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delamanid for Extensively Drug-Resistant Tuberculosis.
    Gupta R; Geiter LJ; Wells CD; Gao M; Cirule A; Xiao H
    N Engl J Med; 2015 Jul; 373(3):291-2. PubMed ID: 26176402
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.
    Auchynka V; Kumar AMV; Hurevich H; Sereda Y; Solodovnikova V; Katovich D; Setkina S; Yedilbayev A; Skrahin A; Skrahina A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis.
    Ahmed SH; Haider H; Moeed A; Mahmood A; Shivani N; Shuja SH; Hayat J; Jamil B; Fatima R
    Indian J Tuberc; 2024 Jan; 71(1):79-88. PubMed ID: 38296395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Millard J; Rimmer S; Nimmo C; O'Donnell M
    Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.